Literature DB >> 23696069

The clinical utility of below-the-ankle angioplasty using "transmetatarsal artery access" in complex cases of CLI.

Luis Mariano Palena1, Enrico Brocco, Marco Manzi.   

Abstract

OBJECTIVES: To appraise clinical results of foot arteries recanalization using percutaneous retrograde transmetatarsal arteries access followed by retrograde recanalization of foot and tibial vessels.
BACKGROUND: Arterial revascularization by means of percutaneous transluminal angioplasty (PTA) is a mainstay in the management of patients with critical limb ischemia (CLI). Nonetheless, when employing standard approaches, success rate remain suboptimal. We report the clinical results of foot arteries recanalization through transmetatarsal artery access.
METHODS: From September 2011 to November 2012, 38 patients (28 men; mean age 73.2 ± 11.4 years) underwent transmetatarsal artery access after antegrade recanalization failure, followed by retrograde recanalization of the foot and tibial vessels. The primary end point was TcPO₂ improvement. The secondary end point was limb salvage rate, amputation-free survival rate and radiation exposure.
RESULTS: Technical success (ability to deliver the balloon across the lesion and inflate it at nominal pressure) was achieved in 33 (86.84%) of cases, with <50% residual stenosis and no complications. Failures were because of spasm or no true lumen re-entry. During follow-up (mean 6.7 ± 2.3 months/range 1-14) clinical improvement was observed in the patients having technical success, with TcPO₂ increasing, from 10.3 ± 7.6 to 50.7 ± 8.2 mm Hg, avoiding major amputations. Amputation-free survival rate calculated by Kaplan-Meier analysis was 81.5% at 12 months. Radiation exposition was major than in patients treated by antegrade way (45.5 ± 56.1 vs. 52.5 ± 11.5 min of fluoroscopy and 69.1 ± 83.2 vs. 94 ± 26.5 Gym(2) of X-ray dose; P < 0.001).
CONCLUSION: Transmetatarsal artery access appears feasible and beneficial in cases with a failed antegrade recanalization and unsuitable for retrograde pedal/plantar access.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  critical limb ischemia; infrapopliteal occlusions; limb salvage; retrograde recanalization

Mesh:

Year:  2013        PMID: 23696069     DOI: 10.1002/ccd.24992

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  6 in total

1.  CIRSE Standards of Practice on Below-the-Knee Revascularisation.

Authors:  Stavros Spiliopoulos; Costantino Del Giudice; Marco Manzi; Lazaros Reppas; Thomas Rodt; Raman Uberoi
Journal:  Cardiovasc Intervent Radiol       Date:  2021-06-25       Impact factor: 2.740

2.  Patency of the arterial pedal-plantar arch in patients with chronic kidney disease or diabetes mellitus.

Authors:  Axel Haine; Alan G Haynes; Andreas Limacher; Tim Sebastian; Wuttichai Saengprakai; Torsten Fuss; Iris Baumgartner
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-02-12

Review 3.  Innovations in the Endovascular Management of Critical Limb Ischemia: Retrograde Tibiopedal Access and Advanced Percutaneous Techniques.

Authors:  Jihad A Mustapha; Larry J Diaz-Sandoval; Fadi Saab
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

4.  Multidisciplinary approach to the diagnosis and management of patients with peripheral arterial disease.

Authors:  Craig M Walker; Frank T Bunch; Nick G Cavros; Eric J Dippel
Journal:  Clin Interv Aging       Date:  2015-07-10       Impact factor: 4.458

5.  Augmented reality navigation to assist retrograde peroneal access for the endovascular treatment of critical limb ischemia.

Authors:  Weifeng Lu; Lixin Wang; Wei Zhou; Weiguo Fu
Journal:  J Vasc Surg Cases Innov Tech       Date:  2019-11-18

6.  Systematic review of inframalleolar endovascular interventions and rates of limb salvage, wound healing, restenosis, rest pain, reintervention and complications.

Authors:  M Machin; H C Younan; A M Guéroult; S Onida; J Shalhoub; A H Davies
Journal:  Vascular       Date:  2021-03-31       Impact factor: 1.285

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.